Fundraising Fox

Trevi Therapeutics

NASDAQ: TRVI

New Haven, US · Delaware corporation · 2 known investors

trevitherapeutics.com ↗

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

BiotechHealthtechin /trevi-therapeutics-inc-@TreviThera

Founders & leadership

EM
Edward MathersDirector
MH
Michael HeffernanDirector
LD
Lisa DelfiniExecutive Officer
JC
James CassellaDirector
DC
Dominick ColangeloDirector
JL
Jennifer L. GoodExecutive Officer, Director
AV
Anne VanLentDirector
WF
William ForbesExecutive Officer
TS
Thomas SciasciaExecutive Officer
DM
David MeekerDirector
JG
Jennifer GoodCo-Founder, President & CEO

Investors · 2

APERTURE Venture PartnersBoston · $1M – $5M
Frazier Life SciencesPalo Alto

Reported raises · per SEC filings

Form D private placements
▶$55MraisedApr 2022 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael HeffernanDirector
  • Thomas SciasciaExecutive Officer
  • David MeekerDirector
  • James CassellaDirector
  • Dominick ColangeloDirector
  • Jennifer L. GoodExecutive Officer, Director
  • William ForbesExecutive Officer
  • Edward MathersDirector
  • Anne VanLentDirector
  • Lisa DelfiniExecutive Officer
Offering amount
$55M
Amount sold
$55M
Sales commissions
$3.3M
Placement agents
Needham & Company, LLC, Oppenheimer & Co. Inc., Aegis Capital Corp., Stifel, Nicolaus & Company, Incorporated
First sale
Apr 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward MathersDirector
  • Michael HeffernanDirector
  • Lisa DelfiniExecutive Officer
  • James CassellaDirector
  • Dominick ColangeloDirector
  • Jennifer L. GoodExecutive Officer, Director
  • Anne VanLentDirector
  • William ForbesExecutive Officer
  • Thomas SciasciaExecutive Officer
  • David MeekerDirector
Offering amount
$3M
Amount sold
$3M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.8MraisedOct 2021 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anne VanLentDirector
  • Dominick ColangeloDirector
  • William ForbesExecutive Officer
  • Jennifer L. GoodExecutive Officer, Director
  • Edward MathersDirector
  • James CassellaDirector
  • Lisa DelfiniExecutive Officer
  • David MeekerDirector
  • Michael HeffernanDirector
  • Thomas SciasciaExecutive Officer
Offering amount
$11.8M
Amount sold
$11.8M
Sales commissions
$709K
Placement agents
Stifel, Nicolaus & Company, Incorporated, Needham & Company, LLC
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$51.9MraisedSep 2018 · 18 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas R. SciasciaExecutive Officer
  • Michael HeffernanDirector
  • Mette Kirstine AggerDirector
  • Ed MathersDirector
  • Chris SeiterExecutive Officer
  • Annie MitsakDirector
  • Jennifer L. GoodExecutive Officer, Director
  • Eran NadavDirector
  • David MeekerDirector
Offering amount
$61.9M
Amount sold
$51.9M
First sale
Jul 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.